.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Deloitte
US Army
Merck
Colorcon
Express Scripts
Fish and Richardson
Cantor Fitzgerald
Baxter

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Inhibitors of bruton'S tyrosine kinase
Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:Jan 21, 2011
Application Number:13/011,258
Claims:1. A compound having the structure: ##STR00057## wherein: A is ##STR00058## L.sub.a is CH.sub.2, O, NH or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; B is ##STR00059## Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, NRS(.dbd.O).sub.x, where x is 1 or 2; R.sub.7 and R.sub.8 are independently selected from among H, unsubstituted C.sub.1-C.sub.4 alkyl, substituted C.sub.1-C.sub.4alkyl, unsubstituted C.sub.1-C.sub.4heteroalkyl, substituted C.sub.1-C.sub.4heteroalkyl, unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted C.sub.3-C.sub.6cycloalkyl, unsubstituted C.sub.2-C.sub.6heterocycloalkyl, and substituted C.sub.2-C.sub.6heterocycloalkyl; or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); wherein R.sub.6, R.sub.7, and R.sub.8 are not all H; R is H or C.sub.1-C.sub.6alkyl; or a pharmaceutically acceptable salts thereof.

2. The compound of claim 1, wherein L.sub.a is O.

3. The compound of claim 2, wherein Ar is phenyl.

4. The compound of claim 3, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2.

5. The compound of claim 4, wherein R.sub.8 is H.

6. The compound of claim 5, wherein R.sub.6 is H.

7. The compound of claim 1 selected from among: (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)-4-(dimethylamino)but-2-en-1-one; (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)-4-methoxybut-2-en-1-one; and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)py- rrolidin-1-yl)but-2-en-1-one.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient.

9. A compound having the structure: ##STR00060## wherein: A is ##STR00061## L.sub.a is CH.sub.2, O, NH or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; B is ##STR00062## Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, NRS(.dbd.O).sub.8, where x is 1 or 2; R.sub.7 and R.sub.8 are independently selected from among H, unsubstituted C.sub.1-C.sub.4 alkyl, substituted C.sub.1-C.sub.4alkyl, unsubstituted C.sub.1-C.sub.4heteroalkyl, substituted C.sub.1-C.sub.4heteroalkyl, unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted C.sub.3-C.sub.6cycloalkyl, unsubstituted C.sub.2-C.sub.6heterocycloalkyl, and substituted C.sub.2-C.sub.6heterocycloalkyl; or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkyl, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); wherein R.sub.6, R.sub.7, and R.sub.8 are not all H; R is H or C.sub.1-C.sub.6alkyl; or a pharmaceutically acceptable salts thereof.

10. The compound of claim 9, wherein L.sub.a is O.

11. The compound of claim 10, wherein Ar is phenyl.

12. The compound of claim 11, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2.

13. The compound of claim 12, wherein R.sub.8 is H.

14. The compound of claim 13, wherein R.sub.6 is H.

15. The compound of claim 9 selected from among: (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-methoxybut-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-methoxybut-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-(dimethylamino)but-2-en-1-one; (E)-1-(4-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)but-2-en-1-one; (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)-4-(dimethylamino)but-2-en-1-one and (E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)but-2-en-1-one.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable excipient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Julphar
Covington
Dow
Teva
Express Scripts
Baxter
Chubb
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot